Amphastar Pharmaceuticals Stock News

Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, Zacks.c

Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals (AMPH) today. The company's shares closed last Monday at $14.19,

Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals ( AMPH – Research Report ) today. The company’s shares closed last Monday at $14.19, close to its 52-week low o

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL) and Homology Medicines

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical

In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI), with a price target of $40.00. The company's

In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report),

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dum

Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $36.00. The company's shares closed

Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN – Research Report) today and set a price

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2019 Results Conference Call March 12, 2020 05:00 PM ET Company Participants Jason Shandell - President Bill Pe

AMPH earnings call for the period ending December 31, 2019.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?